In conversations about addiction recovery, few topics are as misunderstood or as polarizing as Medication-Assisted Treatment (MAT). For many families, the idea of using medication to treat a substance use disorder can seem counterintuitive, leading to fears that it is simply “trading one addiction for another.” This stigma, though pervasive, is one of the most significant barriers to accessing what is, in fact, a safe, effective, and evidence-based form of care.
National data from the country’s leading public health institutions tells an unambiguous story: MAT is a cornerstone of modern addiction medicine. By demystifying this approach and looking at the science behind it, families can make informed decisions grounded in data, not fear, and open the door to a powerful pathway for recovery.
A National Embrace of Evidence-Based Medicine
The shift toward MAT is not a fringe movement; it is a mainstream, data-driven evolution in clinical practice. The 2024 N-SUMHSS from SAMHSA shows that a growing majority of accredited treatment facilities are integrating pharmacotherapy into their programs, reflecting a broad consensus that these medications, when used correctly, save lives and sustain recovery [1].
| Pharmacotherapy | 2021 | 2024 |
| Any pharmacotherapy (SU facilities) | 69.5% | 76.5% |
| Medications for Opioid Use Disorder (MOUD) | 55.3% | 61.7% |
| Medications for Alcohol Use Disorder (MAUD) | 37.9% | 49.9% |
The 12-percentage-point surge in the use of Medications for Alcohol Use Disorder in just three years is particularly striking, indicating a rapid adoption of these life-saving tools. The data is clear: facilities committed to evidence-based care are the ones embracing MAT.
How Medication-Assisted Treatment Actually Works
Contrary to the myths, MAT is not about replacing one drug with another. It is a highly controlled, clinically supervised approach that uses specific, FDA-approved medications to achieve three primary goals: reduce cravings, alleviate withdrawal symptoms, and block the euphoric effects of alcohol and opioids. This provides the neurological stability necessary for a client to fully engage in the intensive therapeutic work of recovery.
For Opioid Use Disorder, the primary medications are buprenorphine (a partial opioid agonist that reduces cravings and withdrawal without producing a significant high), naltrexone (an antagonist that blocks the euphoric effects of opioids), and methadone (a full agonist dispensed in regulated clinics to relieve withdrawal and cravings). For Alcohol Use Disorder, the key medications are naltrexone (which reduces the rewarding effects of alcohol), acamprosate (which stabilizes disrupted brain chemistry to reduce persistent cravings), and disulfiram (which creates an unpleasant physical reaction if alcohol is consumed, serving as a powerful deterrent).
When these medications are part of a comprehensive treatment plan that includes counseling and behavioral therapies, they give individuals the breathing room they need to build a solid foundation for recovery.
Discovery Point Retreat: Integrating Science and Support
At Discovery Point Retreat, we believe in using every evidence-based tool available to help our clients succeed. We view MAT not as a standalone solution but as a vital component of a truly holistic and individualized treatment plan. Our medical and clinical teams work in close collaboration to determine if a client is an appropriate candidate for MAT, ensuring it is administered safely and effectively within a comprehensive schedule of individual therapy, group counseling, and holistic wellness practices.
If you have questions about Medication-Assisted Treatment and whether it is the right choice for you or your loved one, our knowledgeable admissions counselors are here to help. Call us today at 888-547-3077 for a confidential assessment.
Source: Substance Abuse and Mental Health Services Administration. (2025). National Substance Use and Mental Health Services (N-SUMHSS) 2024: Data on Substance Use and Mental Health Treatment Facilities (Publication No. PEP25-07- 013).
